^
    Back
    Association details:
    Biomarker:FGFR3-TACC3 fusion
    Cancer:Adrenal Cortex Carcinoma
    Drug:Balversa (erdafitinib) (FGFR inhibitor, FGFR1 inhibitor, FGFR4 inhibitor, FGFR2 inhibitor, FGFR3 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    J Clin Oncol
    Title:

    Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan–Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors

    Excerpt:
    Tumor shrinkage was also seen in a patient with adrenal carcinoma with FGFR3-TACC3/FGFR2-CCDC6 (FGFR3-TACC3 being the predominant translocation) at 6 mg daily, who received treatment for 10 months before disease progression.
    DOI:
    10.1200/JCO.2014.60.7341
    Trial ID:
    NCT01703481